Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).
The company granted 17,567 restricted stock units of common stock to 11 newly hired non-executive officers on May 16, 2026, under the Ultragenyx Employment Inducement Plan. The RSUs vest over four years, in 25% annual installments.
Details
News Market Reaction – RARE
On May 26, the first trading day after this news, RARE closed 1.07% below the previous close.
Data tracked by StockTitan Argus for the May 26 session.
Key Figures
- RSU grant size
- 17,567 restricted stock units
- Inducement grant to newly hired non-executive officers
- Employees granted
- 11 employees
- Newly hired non-executive officers receiving RSU awards
- Vesting schedule
- 4 years
- RSUs vest in four equal annual installments
- Annual vesting rate
- 25% per year
- Portion of RSUs vesting on each grant-date anniversary
Historical Context
-
Announcement of participation in Bank of America 2026 healthcare conference.
-
Q1 2026 results and reaffirmed full-year revenue guidance and profitability path.
-
Scheduling of Q1 2026 results call and webcast information.
-
Inducement RSU grant to new non-executive officers under Nasdaq Rule 5635(c)(4).
-
FDA acceptance of UX111 BLA resubmission with PDUFA date set.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.